drugset / Trial / NCT06395870
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
33 enrolled
Tianjin Medical University Cancer Institute and Hospital
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39D, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2024-05-09
- Primary completion
- 2026-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-G39D | Cell therapy | — | Other |